FindTrial
Sign In

Role of gene mutation in the drug response enzyme in patients treated with drug clopidrogel in chhatisgarh population

Effect of CYP2C19 and P2Y12 genetic polymorphisms on platelet aggregation in patients on treatment with clopidogrel in Chhattisgarh Population

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/09/036214
Enrollment
200
Registered
2021-09-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I259- Chronic ischemic heart disease, unspecified

Interventions

None listed

Sponsors

Chhattisgarh Council of Science Technology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients more than 18 years of age and of any gender. Patients who have been on clopidogrel therapy for more than seven days. (75mg clopidogrel daily)

Exclusion criteria

Exclusion criteria: Patients with family history of bleeding disorders. Pregnant and lactating women

Design outcomes

Primary

MeasureTime frame
To study the effect of genetic polymorphisms of CYP2C19 and P2Y12 on platelet aggregation in patients on treatment with clopidogrel.Timepoint: 48 MONTHS—

Secondary

MeasureTime frame
To study the effect of genetic polymorphisms of CYP2C19 and P2Y12 on clopidogrel metabolism in patients on treatment with clopidogrel.Timepoint: 48 MONTHS—

Countries

India

Contacts

Public ContactPUGAZHENTHAN T

ALL INDIA INSTITUTE OF MEDICAL SCIENCES (AIIMS)

drpugal23@gmail.com09486279090

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026